Date Time Time Zone Topic Speaker Registration Link

INDICATION

XADAGO (safinamide) is indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Please see additional Important Safety Information on back page and full Prescribing Information.

IMPORTANT SAFETY INFORMATION FOR XADAGO

WARNINGS AND PRECAUTIONS

DOSING GUIDELINES & CONSIDERATIONS

ADVERSE REACTIONS

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact Supernus Pharmaceuticals, Inc. at 1-888-492-3246 (1-888-4XADAGO). You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

©2021 Supernus Pharmaceuticals, Inc. XAD.2021-0003 04/21

Under License from Newron Pharmaceuticals SpA. Supernus Pharmaceuticals, Inc., is
the exclusive licensee and distributor of XADAGO in the United States and Its territories.

©2021. XADAGO is a registered trademark of Zambon SpA.